Autopsy report · NCT00840463

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

“Poor enrolment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 5 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

University of Texas Southwestern Medical Center

Sponsor type

University, hospital or other

Conditions

Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction

Interventions

Ambrisentan; Placebo

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
  “Low enrolment” (88% match in meaning)
• Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
  “lack of enrolment” (84% match in meaning)
• Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
  “Too low enrolment rate” (77% match in meaning)
• Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
  “Low enrolment rate” (76% match in meaning)
• Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
  “difficulty in the enrolment” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.